INTRODUCTION AND OBJECTIVES: Most recent AUA guidelines suggest that an expected drop of estimated glomerular filtration rate (eGFR) below 45 ml/min/1.733 upon radical nephrectomy (RN) should guide decision-making between RN and partial nephrectomy (PN) in patients with anatomically complex tumors. However, limited clinical tools are available to help with this assessment. Here, we examine the correlation between nuclear renal scan (NRS) -measured split renal function (nSRF) and renal parenchyma anatomic-measured (volumetric-estimated) split renal function (aSRF) in patients who underwent RN. We further assess the predictive value of nSRF and aSRF in anticipating post-operative eGFR decline after RN.
INTRODUCTION AND OBJECTIVES: Most recent AUA guidelines suggest that an expected drop of estimated glomerular filtration rate (eGFR) below 45 ml/min/1.733 upon radical nephrectomy (RN) should guide decision-making between RN and partial nephrectomy (PN) in patients with anatomically complex tumors. However, limited clinical tools are available to help with this assessment. Here, we examine the correlation between nuclear renal scan (NRS) -measured split renal function (nSRF) and renal parenchyma anatomic-measured (volumetric-estimated) split renal function (aSRF) in patients who underwent RN. We further assess the predictive value of nSRF and aSRF in anticipating post-operative eGFR decline after RN.
METHODS: From our prospectively-maintained renal database, we identified patients with an enhancing renal mass who had both NRS and multiphase CT performed prior to RN. The average of three varying formulations for calculated renal parenchymal volumes was utilized. aSRF was determined by the ratio of the residual volume (parenchymal volume minus tumor volume) of the diseased kidney to the anatomic-measured total volume of both kidneys. Relationship of the ratio of aSRF to nSRF was examined at increasing tumor sizes to assess for over-estimation or under-estimation of SRF based on the calculated r-value. Spearman correlation coefficients were obtained between decline in eGFR and nSRF/aSRF. RESULTS: 37 patients were identified meeting criteria (median age 59 yrs , median pre-operative eGFR 73.83 ml/min/1.733 ml/min/1.733]). Median maximum tumor diameter was 3.7 cm (IQR 1.7-4.6 cm) and median numerical RENAL nephrometry score was 10 (IQR 8-11). There was a significant and negative correlation with increasing tumor size to the ratio of aSRF to nSRF (r [ -0.58, p [ 0.0005) (Figure 1 ). Median post-RN change in eGFR was -23.66 ml/min/1.733 radiation reduction, cost savings and clinical usefulness of abdominal digital tomosynthesis in the evaluation of renal and proximal ureteral stones relative to stone protocol non-contrast computed tomography (NCCT). The aim of this study is to report on our early clinical experience using pelvic digital tomosynthesis for the evaluation of distal ureteral stones as well as to describe the effective dose (ED) and organ specific doses (ODs) for this technique compared to NCCT.
METHODS: A validated anthropomorphic phantom was placed supine on a digital GE Definium 8000 radiological scanner. A 0.18cc ion chamber was placed on the phantom surface in the center of the imaged field to measure skin entrance exposure during 6 pelvic DTs. Using these data, PCXMC 2.0 software was used to calculate ODs by Monte Carlo simulation and ED using International Commission on Radiological Protection publication 103. Prior work at this institution used a similar phantom to determine the ODs and ED for renal stone protocol NCCT. We have recently used Pelvic DT in our ambulatory clinic to evaluate patients with suspected distal ureteral stones or suggestive symptoms.
RESULTS: The ED for NCCT is significantly higher than pelvic DT (3.04 AE 0.34mSv vs. 1.23 AE 0.65mSv, p[0.013). Mean ODs for pelvic DT are substantially lower compared with NCCT, especially to the testes (0.29 AE 0.41mGy vs. 5.17 AE 3.73mGy, respectively). Clinically, 14 patients had a distal ureteral stone identified on pelvic DT. Stone identification was confirmed in all by ureteroscopic visualization or CT. In 4 of these patients, the stone was not visible on plain KUB.
CONCLUSIONS: In our limited clinical experience, pelvic DT appears to be a useful imaging study for the evaluation of distal ureteral stones in an office setting. Pelvic DT exposes patients to less radiation than NCCT, especially to the radiosensitive gonads. Additionally, it provides cost savings relative to NCCT. Further study is required to compare the sensitivity and specificity of pelvic DT to NCCT for stone identification.
Source of Funding: none

PD23-08 EVALUATION OF FLUCICLOVINE (FACBC) PET SCAN FOR STAGING HIGH-RISK PROSTATE CANCER BEFORE PRIMARY TREATMENT
Mehrdad Alemozaffar*, Akinyemi Akintayo, Olayinka Abiodun-Ojo, Eugene Huang, Dattatraya Patil, Stephanie Giles, Mersiha Torlak, Martin Sanda, David Schuster, Atlanta, GA INTRODUCTION AND OBJECTIVES: The PET radiotracer [18F]-fluciclovine was recently approved by FDA and CMS for detection of metastases in the setting of recurrence after primary treatment for prostate cancer and is undergoing rapid adoption; however, its potential to improve staging and decisions prior to treatment for initial staging has not yet been characterized. We sought to evaluate the potential for fluciclovine-PET to enhance care decisions in the setting of newly diagnosed, high-risk prostate cancer, where standard imaging has suboptimal sensitivity for detecting metastases.
METHODS: Patients with AUA defined high-risk or unfavorable intermediate-risk prostate cancer and clinically localized disease on CT and/or MRI and bone scan already scheduled for robot assisted radical prostatectomy with extended pelvic lymph node dissection (RARP-EPLND) were eligible for this IRB-approved trial. Patients underwent fluciclovine PET-CT according to study parameters. RARP-EPLND with anatomic lymph node packets sent individually was then performed. Histologic findings of metastatic lymph nodes in patients and within specific packets (left pelvic, right pelvic, presacral and nonregional) were then compared to the pre-surgery fluciclovine PET-CT findings to calculate sensitivity and specificity.
RESULTS: 38 patients underwent fluciclovine PET-CT and 35 patients underwent surgery. Mean age was 61.7yrs, mean PSA was 24.4, and median Gleason score was 4þ4. Fluciclovine PET-CT showed suspected extraprostatic disease in 15 patients (39.5%). Three patients were found to have extensive disease on fluciclovine PET-CT and determined to have metastatic disease (confirmed on biopsy, standard of care MRI for bone or clinical response to ADT) and therefore did not undergo surgery. Of the 35 patients undergoing surgery 18/35 (51.4%) had metastatic nodes on histology with fluciclovine PET detecting nodes in 10/18 (55.6%) of these patients for a calculated sensitivity of 61.9%, specificity of 88.2%, PPV of 86.7%, and NPV of 65.2%, with overall accuracy of 73.7%. Diagnostic performance at the lymph node packet level demonstrated a sensitivity of 62.2%, specificity 97.1%, PPV 88.5%, NPV 87.7%, and overall accuracy 87.9%.
CONCLUSIONS: Fluciclovine PET-CT appears to be a valuable tool for pre-treatment staging of patients with high-risk prostate cancer with a high specificity for detection of metastatic lymph nodes. Fluciclovine PET-CT may help in decision-making for treatment options and help guide lymph node dissection during surgery.
Source of Funding: NIH U01-CA113913-11
PD23-09 CONTRAST MEDIA KINETICS IN MULTIPARAMETRIC MRI BEFORE RADICAL PROSTATECTOMY PREDICTS PROBABILITY OF POSTOPERATIVE INCONTINENCE
Florian Alexander Schmid*, Marian Severin Wettstein, Thomas M. Kessler, Andreas Boss, Daniel Eberli, Zurich, Switzerland INTRODUCTION AND OBJECTIVES: While radical prostatectomy (RP) renders good cancer control, urinary incontinence (UI) remains a major morbidity issue and significantly influences the postoperative quality of life. With the possibility of predicting the chances of UI, urologists receive an important tool in their prognostic armamentarium, which will influence consulting and treatment strategies. The aim of the study was to use data from routine preoperative MRI to estimate the risk of incontinence after RP.
METHODS: We analyzed patients who underwent robotassisted RP for localized prostate cancer at our institution between July 2015 and April 2017. Preoperatively, all patients received a multiparametric MRI of the prostate (3 Tesla Siemens Magnetom). Prospectively collected questionnaires regarding UI were evaluated one year postoperatively (ICIQ-Score). "Tissue 4D" software from Siemens on "Syngo Multimodality Workplace" was used to measure the contrast media (CM) kinetics (median initial area under the curve for the first 60 seconds after injection of CM [median iAUC]). With this technique, we were able to visualize the preoperative perfusion quality of the pelvic floor (levator ani muscle) in comparison to the surrounding pelvic muscle structures (reference). Outcomes were dichotomized into groups "continent" (ICIQ-score [ 0-5) and "incontinent" (ICIQ-score > 5). In each patient, we determined the ratio between the median iAUC of the levator ani muscle to the median iAUC of the surrounding pelvic muscle structures. The resulting perfusion ratios among the group of continent patients were then compared to the ratios of the incontinent patients. RESULTS: In total 42 patients were included in this study (n[22 in "continent", n[20 in "incontinent" group) . The groups did not differ with regard to clinically relevant characteristics (age, PSA, Gleason-Score and nerve sparing). The perfusion ratio from the continent group was significantly higher than the one from the incontinent group (1.61 vs. 1.15, respectively; difference in perfusion ratios [ 0.45; 95% confidence interval (CI): 0.09 -0.81, p [ 0.015). A further analysis of excellent outcomes (ICIQ [ 0) vs. poor outcomes (ICIQ > 10) of 10 patients in each group, the perfusion ratio of excellent outcomes was also significantly higher (1.48 vs. 0.94, respectively; difference in perfusion ratios [ 0.53; 95% CI: 0.04 -1.03, p [ 0.036).
CONCLUSIONS: Our data demonstrate a promising new strategy to assess the perfusion of pelvic muscle structures with CM kinetics to predict continence after RP. This may facilitate preoperative patient consulting and decision making.
